CAST Regimen for GvHD Prophylaxis: A CIBMTR Propensity Score-Matched Analysis
- PMID: 39209024
- PMCID: PMC11701941
- DOI: 10.1016/j.jtct.2024.08.015
CAST Regimen for GvHD Prophylaxis: A CIBMTR Propensity Score-Matched Analysis
Abstract
Previously, we reported excellent results with the combination of post-transplant cyclophosphamide (PTCy), abatacept, and a short course of tacrolimus (CAST) for the prevention of graft-versus-host disease (GvHD) following peripheral blood haploidentical transplantation. To further substantiate these results, we performed a propensity score-matched analysis. Patients enrolled in the CAST trial were matched with patients from a contemporaneous cohort from the Center for International Blood and Marrow Transplant Research database who received PTCy, tacrolimus, and mycophenolate mofetil, using nearest neighbor propensity score matching. An excellent balance between pairs was achieved as measured by the density distribution and standardized differences of covariates (median 0.09). The rates of acute GvHD grades II to IV at day +120 and 1-year GvHD- and relapse-free survival were 16.7% and 66.7% in the CAST cohort versus 28.6% and 47.6% in the control group, respectively. This trend did not reach statistical significance (P = .14 and .07), possibly due to the small numbers of patients and events. On the other hand, CAST was associated with a statistically significant reduction in the incidence of relapse (9.5% versus 26.2%, P = .045) with improved disease-free survival (85.7% versus 61.9%, P = .01). Our data provides a strong impetus to examine CAST in a randomized clinical trial.
Keywords: CAST; GvHD prevention; Haploidentical transplant; Propensity score case-control analysis.
Copyright © 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
ASH received unrestricted educational grant and advisory board honorarium from BMS.
References
Publication types
MeSH terms
Substances
Grants and funding
- R01 AI158861/AI/NIAID NIH HHS/United States
- R01 CA231838/CA/NCI NIH HHS/United States
- U01 AI126612/AI/NIAID NIH HHS/United States
- R21 AG077024/AG/NIA NIH HHS/United States
- U24 HL157560/HL/NHLBI NIH HHS/United States
- R01 HL155741/HL/NHLBI NIH HHS/United States
- C0000008/CL/CLC NIH HHS/United States
- OT3 HL147741/HL/NHLBI NIH HHS/United States
- 27307C0011/ES/NIEHS NIH HHS/United States
- R01 CA100019/CA/NCI NIH HHS/United States
- R01 AI150999/AI/NIAID NIH HHS/United States
- 27398C0011/ES/NIEHS NIH HHS/United States
- P01 CA111412/CA/NCI NIH HHS/United States
- 27307C0009/ES/NIEHS NIH HHS/United States
- R01 AI128775/AI/NIAID NIH HHS/United States
- U24 CA076518/CA/NCI NIH HHS/United States
- U24 HL138660/HL/NHLBI NIH HHS/United States
- U01 AI069197/AI/NIAID NIH HHS/United States
- R01 CA231141/CA/NCI NIH HHS/United States
- UG1 HL069254/HL/NHLBI NIH HHS/United States
- R01 CA218285/CA/NCI NIH HHS/United States
- R01 CA262899/CA/NCI NIH HHS/United States
- 27305C0011/ES/NIEHS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Miscellaneous